Physician profile
Benjamin Hayden
NPI 1841236437
$3,420.58
in general payments reported to CMS, 2019-2025
26 companies · $989 in 2025
The $989 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $471 · 2022: $98.48 · 2023: $1,402 · 2024: $460 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,851.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $392.89 | 2021-2025 | Breztri, Farxiga |
| Alexion Pharmaceuticals, INC. | $329.68 | 2023-2024 | Ultomiris |
| Abbvie INC. | $319.13 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $227.08 | 2023-2024 | Dupixent |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $198.81 | 2021-2023 | Caplyta |
| Amgen INC. | $163.97 | 2023-2025 | Otezla, Otezla |
| Abbott Laboratories | $149.76 | 2023 | Freestyle Libre 3 |
| Gilead Sciences, INC. | $148.53 | 2023-2024 | Epclusa |
| Neurocrine Biosciences, INC. | $146.61 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Insulet Corporation | $123.94 | 2025 | Omnipod |
| Astellas Pharma US INC | $119.85 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.22 | 2022-2025 | Jardiance, Tradjenta |
| Novo Nordisk INC | $102.92 | 2025 | Ozempic |
| Boston Scientific Corporation | $92.08 | 2025 | Intracept |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $86.57 | 2023 | Valtoco |
| Janssen Pharmaceuticals, INC | $82.77 | 2021-2025 | Invega Sustenna |
| Stryker Corporation | $81.82 | 2025 | |
| Dynavax Technologies Corporation | $80.83 | 2024 | Heplisav-B |
| Axsome Therapeutics, INC. | $78.63 | 2023 | Auvelity |
| Itamar Medical INC | $57.45 | 2023 | Watchpatone |
| Alkermes, INC. | $51.54 | 2021 | |
| Exact Sciences Corporation | $48.43 | 2023-2024 | Cologuard Collection Kit |
| Indivior INC. | $45.90 | 2022-2023 | Perseris |
| Vanda Pharmaceuticals INC. | $35.84 | 2025 | Fanapt |
| Xeris Pharmaceuticals, INC. | $19.33 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Hayden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.